Tiziana Life Sciences is a clinical stage biotechnology company that specializes in the developing transformative therapies for inflammatory diseases and cancer related to the liver. Our clinical pipeline includes drug assets for NASH, Crohn's, and hepatocellular carcinoma. Tiziana is led by a team of highly qualified executives with extensive drug development and commercialization experience. Website: www.tizianalifesciences.com
Symbol: TLSA/NASDAQ and TILS/AIM
INVESTMENT HIGHLIGHTS: *Innovative platform technology for oral and nasal formulations can transform the administration of Monoclonal Antibodies('mAbs') *Two de-risked assets in clinical evaluation that target the root causes of autoimmune/inflammatory diseases and cancer *Milciclib has received 'Orphan Drug Designation' in US and EU for treatment of thymic carcinoma/thymoma(TC/T) *Assets for unmet needs in multi-billion dollar addressable markets *NASH - $35 billion; Crohns Disease - $10 billion per year(2025); Liver Cancer - $1.5 billion/year by 2022 *Strong Intellectual Property with 255 patents approved and more than 30 pending *Experienced and successful biotech management team *A 'leveragable' biotechnology platform for use in additional therapeutics *Will list jointly on Nasdaq/London Price: Around $7.00 per ADS(1 ADS represents 10 shares) Market Cap Post-Offering: Estimated $110-125 Million TRADES: PENDING IPO